Mackenzie Financial
KRTX

Mackenzie Financial’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Mackenzie Financial’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,372
Closed -$270K – 1632
2022
Q4 		$270K Sell
1,372
-330
-19% -$70.8K ﹤0.01% 1126
2022
Q3 		$383K Sell
1,702
-102
-6% -$20.6K ﹤0.01% 1011
2022
Q2 		$228K Buy
+1,804
New +$207K ﹤0.01% 1228

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mackenzie Financial's KRTX Position: Q1 2023 in Review

Mackenzie Financial sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2023, closing a stake of 1,372 shares — an estimated $270K sold.

Mackenzie Financial first reported a position in KRTX in Q2 2022 and held it in 3 quarters. The position peaked at $383K in Q3 2022. 246 funds tracked by Wall St. Rank hold KRTX as of Q1 2023.

  • Mackenzie Financial reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Mackenzie Financial sold 1,372 Karuna Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $270K.
  • Mackenzie Financial first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2022 and held it in 3 quarters.
  • Mackenzie Financial's Karuna Therapeutics, Inc. Common Stock position peaked at $383K in Q3 2022.
  • 246 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Mackenzie Financial's 13F filing for Q1 2023, filed 24 Apr 2023.